Transplantation
Research
The Weill Cornell-Rogosin program continues to strive to improve the care of patients needing transplant as well as the outcomes of transplant through collaborative research. Current projects include:
- Evaluating steroid-free regimens for selected patients
- Utilization of a new non-invasive urine test to diagnose rejection
- Developing new combinations of drugs to reduce rejections
- Transplantation for HIV positive patients who meet certain criteria
- Following patients long term to help ascertain cardiovascular risk factors in transplant recipients.
- The Rogosin Institute Iris & B. Gerald Cantor Clinical Research Laboratory provides clinical testing and runs tests for cyclosporine and tacrolimus
- Clinical research in the developmental process of many commercially available medications for the treatment of cholesterol and renal disorders.
- Development of LDL-apheresis, an extracoporeal treatment for patients with severe hypercholesterolemia. The treatment device, Liposorber LA-15, is now available throughout the US and Europe
- Development of a lipid emulsion, still in the investigational stage, which may be a potential treatment/prevention for endotoxemia. The Rogosin Institute was responsible for the Phase I, first time in man studies using this emulsion.
Related Links
- Iris Cantor Women's Health Center, NewYork-Presbyterian/Weill Cornell
- Dr. Sandip Kapur on NY1: Simple Non-invasive Test Can Help Predict Odds of Organ Rejection
- Father Gives Kidney to His Daughter
- Wiz Of The Bravehearts Donates Kidney To His Daughter
- Sandip Kapur, MD, Appointed Chief of Transplantation Surgery
